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ABSTRACT
Background  Anti-tumour necrosis factor (anti-TNF) 
therapy has been associated with reports of rapid severe 
progression of rheumatoid arthritis-associated interstitial 
lung disease (RA-ILD). However, reports also exist of 
favourable responses to anti-TNF therapy in patients with 
ILD. The aim of this study was to examine the inﬂ  uence of 
anti-TNF therapy on mortality in patients with pre-existing 
RA-ILD.
Methods  Using data from the British Society for 
Rheumatology Biologics Register, a national prospective 
observational study, 367 patients with pre-existing RA-ILD 
were identiﬁ  ed (299 treated with anti-TNF therapy and 68 
treated with traditional disease-modifying antirheumatic 
drugs (DMARDs)).
Results  70/299 patients (23%) in the anti-TNF cohort 
died after a median follow-up of 3.8 years compared 
with 14/68 (21%) in the DMARD cohort after a median 
follow-up of 2.1 years. The mortality was 68 deaths/1000 
person years (pyrs) (95% CI 53 to 86) in the anti-TNF 
cohort and 92/1000 pyrs (95% CI 50 to 155) in the 
DMARD cohort, generating an age- and sex-adjusted 
mortality rate ratio (aMRR) of 1.26 (95% CI 0.69 to 2.31). 
After further adjustment for potential confounders, the 
aMRR fell to 0.81 (95% CI 0.38 to 1.73) for the anti-TNF 
cohort compared with the DMARD cohort. RA-ILD was the 
underlying cause of death in 15/70 (21%) and 1/14 (7%) 
patients in the anti-TNF and DMARD cohorts, respectively.
Conclusion  The mortality in patients with RA-ILD is 
not increased following treatment with anti-TNF therapy 
compared with traditional DMARDs. The proportion of 
deaths attributable to RA-ILD is higher in patients treated 
with anti-TNF therapy, although reporting bias may exist.
INTRODUCTION
Rheumatoid arthritis (RA) is associated with 
extra-articular manifestations in around 40% of 
patients.1 2 Respiratory manifestations are com-
mon and include airways, pleural and interstitial 
disorders. Rheumatoid arthritis-associated intersti-
tial lung disease (RA-ILD) is a non-neoplastic disor-
der resulting from damage to the lung parenchyma 
by varying patterns of inﬂ  ammation and ﬁ  brosis.3 
Estimates of prevalence vary widely from 1% to 
80%, the broad range reﬂ  ecting differences in dis-
ease deﬁ  nitions and populations studied.4
RA-ILD is associated with a signiﬁ  cant mortal-
ity. Estimates of 2-year mortality in patients with 
Inﬂ  uence of anti-TNF therapy on mortality in patients 
with rheumatoid arthritis-associated interstitial 
lung disease: results from the British Society for 
Rheumatology Biologics Register
W G Dixon,1 K L Hyrich,1 K D Watson,1 M Lunt,1 BSRBR Control Centre Consortium,2 
D P M Symmons1 on behalf of the British Society for Rheumatology Biologics 
Register
1Arthritis Research UK 
Epidemiology Unit, Manchester 
Academic Health Sciences 
Centre, University of 
Manchester, Manchester, UK




Professor Deborah Symmons, 
University of Manchester, 
Stopford Building, Oxford Road, 
Manchester M13 9PT, UK; 
deborah.symmons@man-
chester.ac.uk
Accepted 3 December 2009
prevalent disease are >20%.5 6 RA-ILD is the direct 
cause of death in 4% of unselected patients with 
RA, while featuring on the death certiﬁ  cate in 6%.7 
Following the introduction of anti-tumour necrosis 
factor (anti-TNF) therapies for patients with RA, 
there have been a number of case reports and case 
series documenting either a rapid progression of 
pre-existing RA-ILD or the development of new-
onset interstitial disease. Such reports exist for each 
of the three currently licensed anti-TNF therapies: 
inﬂ  iximab (INF), etanercept (ETA) and adalimumab 
(ADA).8–14 Nineteen out of 20 of these cases of pro-
gressive RA-ILD occurred less than 3  months after 
starting anti-TNF therapy, providing a persuasive 
argument for causality despite the limitations of 
spontaneous pharmacovigilance. Eight of the 20 
cases were fatal. These reports have led to the inclu-
sion of ILD as an ‘undesirable effect’ in the Summary 
of Product Characteristics for each of the three 
drugs. However, in direct contrast, there are also 
reports of anti-TNF therapy   stabilising or improving 
lung function in patients with RA-ILD.15–17 These 
paradoxical effects are, however, supported by 
animal models of both   proﬁ  brotic and antiﬁ  brotic 
effects of TNF in the lung.18
The aim of this study was to examine the inﬂ  u-
ence of anti-TNF therapy on all-cause and ILD-




The subjects for this analysis were participating in 
a large national prospective observational study, 
the British Society for Rheumatology Biologics 
Register (BSRBR). The methods of patient recruit-
ment and follow-up have been described in detail 
elsewhere.19 Brieﬂ  y, the study was established in 
2001 to examine the long-term safety of biologi-
cal drugs in patients with RA. Recruitment targets 
of 4000 patients with RA treated with each of the 
three anti-TNF drugs, as well as 4000 biologic-
naïve patients with active RA receiving standard 
disease-modifying antirheumatic drug (DMARD) 
therapy, were set in the ﬁ  rst years of the study. 
UK national guidelines recommend that anti-TNF 
drugs are reserved for patients with active RA 
(deﬁ  ned as a 28-joint count disease activity score 
(DAS28) >5.1) despite previous therapy with at 
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least two DMARDs, one of which should be methotrexate,20 
and that ‘any clinician prescribing these medications must (with 
the patient’s permission) undertake to register the patient with 
the BSRBR and forward information on dosage, outcome and 
toxicity on a six-monthly basis’.21 Recruitment targets for the 
ETA cohort were met in 2005, for the INF cohort in 2007 and 
for the ADA cohort in 2008. No accurate ﬁ  gures for anti-TNF 
penetration in the UK RA population exist, although estimates 
of around 7% have been suggested.22 Before recruitment targets 
were met, we estimated that >80% of anti-TNF treated patients 
with RA in the UK were registered on the BSRBR.
Anti-TNF cohort
Analysis was restricted to patients registered with the BSRBR 
with a physician diagnosis of RA who were commencing an 
anti-TNF drug as their ﬁ  rst biological drug. Patients registered 
more than 6  months after the start of biological therapy were 
excluded. All patients were registered before 30 June 2008.
Comparison cohort
The cohort of biologic-naïve patients with active RA was 
recruited in parallel (see authorship list of the BSR Control Centre 
Consortium) and followed using identical methodology.19 These 
patients have a physician diagnosis of RA with active disease 
(guideline DAS28 ≥4.2) despite current treatment with a tradi-
tional DMARD and are naïve to biological agents. Comparison 
patients also had to be registered before 30 June 2008.
Baseline assessment
Baseline information for both cohorts included demographic 
characteristics, disease duration, 28 swollen and 28 tender joint 
counts, erythrocyte sedimentation rate and/or C-reactive pro-
tein and patient global assessment which enables calculation 
of a DAS28 score.23 Rheumatoid factor (RhF) positivity was 
deﬁ  ned as the presence (ever) of a titre ≥1/40. The   presence 
of baseline RA-ILD was based on the response to the follow-
ing question in the consultant baseline questionnaire: ‘Has the 
patient ever had any of the following systemic features (of 
RA): pulmonary   ﬁ  brosis?’ Other extra-articular manifestations 
of rheumatoid arthritis (EARA) were deﬁ  ned as the presence 
(ever) of one or more of sicca syndrome, serosal involvement 
(pleuritis/pericarditis), eye involvement, systemic vasculitis or 
nailfold vasculitis. Details of all previous DMARD therapy and 
all current medications were obtained, as well as smoking his-
tory and comorbidity. Patients completed a Health Assessment 
Questionnaire (HAQ) adapted for British use.24
Follow-up
Data on changes in therapy, disease activity and the occur-
rence of adverse events were captured in three ways: 6-monthly 
rheumatologist questionnaire, 6-monthly patient diary and by 
‘ﬂ  agging’ with the UK Ofﬁ  ce for National Statistics (ONS) who 
provided information on mortality including cause of death 
coded according to the International Classiﬁ  cation of Diseases 
10 (ICD-10).
After 3  years of follow-up, consultant questionnaires were 
sent annually and patient diaries were no longer sent. Deaths 
occurring before 30 June 2008, notiﬁ  ed from any source, were 
included in the all-cause mortality analyses. Data were collected 
until December 2008 to allow for a delay between the date of 
death and the notiﬁ  cation of death being received by the BSRBR 
from the ONS. Analysis by cause of death was limited to those 
deaths where notiﬁ  cation had been received from the ONS.
RA-ILD was identiﬁ  ed from the death certiﬁ  cate using the 
ICD-10 codes J84.1 ‘Interstitial pulmonary diseases with 
  ﬁ  brosis’, J84.9 ‘Interstitial pulmonary disease, unspeciﬁ  ed’ and 
M05.1 ‘Rheumatoid lung’. RA-ILD deaths were categorised 
into recording of RA-ILD anywhere on the death certiﬁ  cate 
and RA-ILD as the underlying cause of death (a subset of the 
former).
Statistical analysis
Patients contributed person years (pyrs) of follow-up from their 
registration date (anti-TNF start date for the anti-TNF cohort) 
until the cut-off date (30 June 2008) or the date of death, which-
ever came sooner. Patients continued to contribute pyrs for the 
duration of follow-up, irrespective of drug discontinuation, 
switching between anti-TNF therapies (for the anti-TNF cohort) 
or the return of consultant questionnaires. Patients could switch 
from the DMARD cohort to the anti-TNF cohort. Such patients 
contributed pyrs of follow-up to the DMARD cohort up to the 
date an anti-TNF drug was started and subsequent follow-up to 
the anti-TNF cohort. Patients could not switch from the anti-
TNF to the DMARD cohort.
Mortalities are presented as the number of deaths/1000  pyrs 
with 95% CI. Mortality rate ratios (MRRs) were calculated 
using Cox regression, comparing the anti-TNF cohort with the 
DMARD cohort. Adjustment was made for age, gender and 
calendar year of recruitment. Multivariable regression was per-
formed with additional confounders identiﬁ  ed from an a priori 
list of possible confounders including smoking (current/former/
never), diabetes, chronic obstructive pulmonary disease (COPD)/
asthma, prior tuberculosis, disease severity (HAQ, DAS28 and 
disease duration as continuous variables), EARA, RhF   positivity, 
number of prior DMARDs, baseline methotrexate use (yes/no) 
and baseline steroid use (yes/no). Analysis exploring potential 
confounders was done both by limiting analysis to patients 
with complete data and by imputing missing data to include 
all patients. True confounders were identiﬁ  ed by sequentially 
including each confounder in the regression model, and including 
in the multiple variable regression those confounders that indi-
vidually changed the estimation after adjustment by more than 
10%.25 All analyses were performed using Stata 9.2 (StataCorp, 
College Station, Texas, USA).
RESULTS
A total of 13 883 patients were included in the analyses, 3464 
in the DMARD cohort and 10 649 patients had ever received an 
anti-TNF drug; 210 patients switched from the DMARD cohort 
to the anti-TNF cohort and contributed pyrs to both cohorts. In 
all, 2725 patients in the anti-TNF cohort were known to have 
been exposed to more than one anti-TNF drug during follow-up. 
The anti-TNF treated cohort had more severe disease than the 
DMARD cohort (table 1).
Sixty-eight patients in the DMARD cohort and 299 patients 
in the anti-TNF cohort had physician-reported RA-ILD at 
baseline. The RA-ILD cohorts were older and comprised pro-
portionally more men than patients without RA-ILD (table 1). 
They also had slightly higher disease activity and longer dis-
ease duration. Patients with RA-ILD at baseline had more other 
EARA than patients without RA-ILD, as well as more COPD/
asthma. Higher proportions of patients with RA-ILD had ever 
smoked. Fewer patients with RA-ILD were using methotrexate 
at   baseline. All subsequent analyses are limited to patients with 
baseline RA-ILD. Three patients with baseline RA-ILD contrib-
uted pyrs to both cohorts.
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gender, the adjusted mortality rate ratio (aMRR) was 1.26 (95% 
CI 0.69 to 2.31) for the anti-TNF RA-ILD cohort compared with 
the DMARD RA-ILD cohort. However, after full adjustment for 
potential confounders, the aMRR fell to 0.81 (0.38 to 1.73). Of 
the potential confounders, age, gender, calendar year of entry, 
disease duration, HAQ, DAS28 score, COPD/asthma, baseline 
steroid use and baseline methotrexate use were included in the 
multivariate model. The only signiﬁ  cant predictors of mortality 
were age (HR 2.28 (95% CI 1.64 to 3.15) per decade) and DAS28 
score (HR 1.43 (95% CI 1.11 to 1.85) per unit increase).
RA-ILD was the underlying cause of death in 15/70 patients 
(21%) who died in the anti-TNF RA-ILD cohort compared with 
1/14 (7%) in the DMARD RA-ILD cohort (table 3). The propor-
tion of deaths where RA-ILD was recorded anywhere on the 
death certiﬁ  cate was also higher in the anti-TNF RA-ILD cohort 
Considering only patients with RA-ILD, the anti-TNF RA-ILD 
cohort was younger with more severe disease including more 
EARA than the DMARD RA-ILD cohort. COPD/asthma was 
balanced in the two cohorts, as was smoking status. The median 
pyrs of follow-up per patient was 2.1  years for the DMARD 
RA-ILD cohort and 3.8  years for the anti-TNF RA-ILD cohort 
(table 2). Fourteen of 68 (21%) of the DMARD RA-ILD cohort 
died during this follow-up period compared with 70 of 299 (23%) 
of the anti-TNF RA-ILD cohort. None of the three patients who 
contributed pyrs to both the DMARD and the anti-TNF RA-ILD 
cohorts died.
The all-cause mortality was 68 deaths/1000 pyrs (95% 
CI 53 to 86) in the anti-TNF RA-ILD cohort compared with 92 
deaths/1000 pyrs (95% CI 50 to 155) in the DMARD RA-ILD 
cohort (table 2 and ﬁ   gure 1). After adjustment for age and 
Table 1 Baseline  characteristics
 









Mean (SD) age (years) 60 (12) 68 (9) 56 (12) 63 (10)
Females, n (%) 2462 (73) 60 7889 (76) 57
Mean (SD) DAS28  5.1 (1.3) 5.2 (1.2) 6.5 (1.0) 6.7 (1.0)
Mean (SD) HAQ  1.5 (0.8) 1.8 (0.7) 2.0 (0.6) 2.1 (0.5)
Median (IQR) disease duration (years) 6 (1–15) 12 (5–22) 11 (6–19) 12 (7–20)
RhF positivity, n (%) 1953 (58) 50 (74) 6616 (64) 226 (76)
Baseline EARA, n (%) 602 (18) 26 (38) 2812 (27) 163 (55)
Baseline steroid use, n (%) 759 (22) 37 (54) 4522 (44) 171 (57)
Diabetes, n (%) 219 (7) 10 (15) 592 (6) 17 (6)
COPD/asthma, n (%) 622 (18) 19 (28) 1352 (13) 73 (25)
Smoking, n (%)
  Current 796 (23) 16 (24) 2270 (22) 61 (20)
  Former 1338 (39) 36 (53) 3878 (37) 166 (56)
  Never 1245 (37) 16 (24) 4139 (40) 72 (24)
Median (IQR) number of prior DMARDs 2 (1–3) 4 (2–5) 4 (3–5) 4 (3–5)
Baseline methotrexate use, n (%) 2097 (64) 20 (30) 5693 (57) 109 (38)
COPD, chronic obstructive pulmonary disease; DAS28, disease activity score; DMARD, disease-modifying antirheumatic drug; EARA, 
extra-articular manifestations of rheumatoid arthritis; HAQ, Health Assessment Questionnaire; RA-ILD, rheumatoid arthritis-associated 
interstitial lung disease; RhF, rheumatoid factor; TNF, tumour necrosis factor.
Table 2  Mortality in DMARD and anti-TNF cohorts stratiﬁ  ed by baseline RA-ILD
 
DMARD Anti-TNF
No baseline RA-ILD Baseline RA-ILD No baseline RA-ILD Baseline RA-ILD
Patients (n) 3396 68 10350 299
Total pyrs of follow-up 8782 152 38423 1026
Median (IQR) follow-up 
per person (years)
2.6 (1.7–3.6) 2.1 (1.3–3.1) 3.9 (2.7–4.9) 3.8 (2.0–4.7)
Deaths
 All-cause  (n) 181 14 635 70
  All-cause mortality/1000 pyrs 21 (18 to 24) 92 (50 to 155) 17 (15 to 18) 68 (53 to 86)
  RA-ILD as cause, n (%) 2 (1) 1 (7) 14 (2) 15 (21)
  RA-ILD on cert, n (%) 4 (2) 2 (14) 25 (4) 24 (34)
MRR (unadjusted (95% CI)) Referent 0.74 (0.42 to 1.33)
MRR (adjusted for age and 
gender (95% CI))
Referent 1.26 (0.69 to 2.31)
MRR (adjusted for age and gender 
and calendar year (95% CI))
Referent 1.14 (0.58 to 2.26)
MRR (fully adjusted* (95% CI))
   Using patients with complete 
data sets
Referent 0.80 (0.34 to 1.87)
  Using imputed data   Referent   0.81 (0.38 to 1.73)
*Confounders included in multivariable model (adjusting point estimate by >10%) included age, gender, calendar year of entry, 
disease duration, HAQ, DAS28, COPD/asthma, baseline steroid use and baseline methotrexate use. (RhF, EARA, diabetes and smoking 
not identiﬁ  ed as confounders.)
COPD, chronic obstructive pulmonary disease; DAS28, disease activity score; DMARD, disease-modifying antirheumatic drug; EARA, 
extra-articular manifestations of rheumatoid arthritis; HAQ, Health Assessment Questionnaire; MRR, mortality rate ratio; pyrs, person 
years; RA-ILD, rheumatoid arthritis-associated interstitial lung disease; RhF, rheumatoid factor; TNF, tumour necrosis factor.
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than in the DMARD RA-ILD cohort (24/70 (34%) vs 2/14 (14%)). 
The age- and sex-adjusted MRR for deaths where ILD featured 
on the death certiﬁ  cate was 2.63 (95% CI 0.60 to 11.45) for the 
anti-TNF RA-ILD cohort compared with the DMARD RA-ILD 
cohort. We also explored the frequency of RA-ILD-related deaths 
in patients without baseline RA-ILD. The proportion of deaths 
for which RA-ILD was the underlying cause was signiﬁ  cantly 
lower in patients who did not have pre-existing RA-ILD (14/635 
(2%) deaths in the anti-TNF cohort vs 2/181 deaths (1%) in the 
DMARD cohort). Similarly, the proportions of deaths where 
RA-ILD was recorded anywhere on the certiﬁ  cate were much 
lower in patients without baseline RA-ILD (25/638 deaths (4%) 
in the anti-TNF cohort vs 4/181 deaths (2%) in the DMARD 
cohort). When comparing mortalities in patients with RA-ILD 
compared with no baseline RA-ILD, baseline RA-ILD was a 
strong predictor of all-cause mortality in both the anti-TNF and 
DMARD cohorts (age- and sex-adjusted MRR 2.85 (95% CI 2.22 
to 3.66) and 2.69 (95% CI 1.55 to 4.67), respectively).
DISCUSSION
We have shown that the mortality in patients with RA-ILD is 
not increased following treatment with anti-TNF therapy com-
pared to treatment with traditional DMARDs. However, the 
proportion of deaths attributable to RA-ILD is higher in patients 
treated with anti-TNF therapy.
There are a number of methodological issues to consider when 
interpreting these data. The ﬁ  rst important issue is what the 
reporting of baseline RA-ILD constitutes, and whether this may 
have differed between the treatment arms. Patients with base-
line RA-ILD were identiﬁ  ed in response to the question on the 
consultant baseline questionnaire: ‘Has the patient ever had any 
of the following systemic features (of RA): pulmonary   ﬁ  brosis?’. 
Patients may have been misclassiﬁ  ed in either direction. It is 
possible that patients reported to have baseline RA-ILD did not 
have the disease. Such misclassiﬁ  cation was unlikely to have 
been imbalanced in the two treatment arms or to introduce bias. 
The opposite misclassiﬁ  cation is more likely: where patients 
with true RA-ILD at baseline were not reported to the register. 
Most rheumatologists do not systematically screen for ILD and 
they may have varying thresholds for initiating investigations. 
Severe ILD is more likely to be diagnosed than mild ILD.
Anti-TNF safety signals in patients with RA-ILD have been 
published since 2004.26 Consequently, clinicians may have 
been less inclined to prescribe anti-TNF therapy to patients 
with severe RA-ILD. As increasing RA-ILD severity is probably 
associated with increased mortality, such a selection bias would 
relatively increase the mortality in the DMARD cohort and lead 
to a reduction in our estimates of MRR. We should therefore 
conclude from our results that the way in which UK rheumatol-
ogists select patients with pre-existing RA-ILD to receive anti-
TNF therapy is not leading to an increase in all-cause mortality, 
rather than concluding that anti-TNF therapy does not increase 
the mortality in unselected patients with RA-ILD.
Despite the original cohort size of nearly 14  000 patients, 
there were only 364 patients with baseline RA-ILD, of whom 
84 (23%) died. The small population size has implications for 
the precision of the estimated relative risk of death attributable 
to anti-TNF therapy, and is particularly sensitive to the number 
of deaths in the DMARD RA-ILD cohort, given its smaller size. 
The aMRR of 0.81 (95% CI 0.38 to 1.73) has wide CIs follow-
ing adjustment for multiple potential confounders. Although 
the number of deaths was relatively small, the ﬁ  nal inclusion of 
eight confounders did not contravene guidance that there should 
be more than 10 events per variable in the model.27 The preci-
sion of the estimate could be narrowed with a larger population 
size. However, this result represents the outcome of a national 
study conducted over 7 years, and we must accept it as the best 
available estimate of risk with respect to this important clinical 
question at this stage.
We were able to measure and adjust for many potential con-
founders. These included smoking, other EARA and RhF posi-
tivity, all of which were more common in patients with baseline 
RA-ILD. While stepwise adjustment led to moderate changes in 
the aMRR point estimate, ﬂ  uctuation was always around unity, 
reinforcing the absence of an increased risk. As with most obser-
vational studies, there may be remaining unmeasured or residual 
confounding. As mentioned above, RA-ILD severity may have 






RA-ILD on death certiﬁ  cate
  ILD as immediate cause of death 1 (7) 15 (22)
  ILD present on death certiﬁ  cate 2 (14) 24 (35)
Underlying cause of death by ICD-10 chapter
  Certain infectious and parasitic diseases –   3 (4)
  Neoplasms 5 (36)   9 (13)
  Diseases of the blood and blood-forming organs –   1 (1)
  Endocrine, nutritional and metabolic diseases –   1 (1)
  Circulatory 4 (29) 13 (19)
  Respiratory 3 (21) 20 (29)
 Digestive –   2  (3)
  Musculoskeletal and connective tissue 2 (14) 17 (24)
 Genitourinary –   2  (3)
  External causes –   1 (1)
 Missing –  1  (1)
Figures represent number (%) of deaths.
*One missing cause of death in anti-TNF cohort. Percentages represent proportion of 69 
patients with a reported cause of death.
DMARD, disease-modifying antirheumatic drug; ILD, interstitial lung disease; RA-ILD, 
rheumatoid arthritis-associated ILD; TNF, tumour necrosis factor.
Figure 1  Inﬂ  uence of anti-TNF therapy on all-cause mortality in 
patients with pre-existing RA-ILD, adjusted for age and gender. Numbers 
in table represent the number of patients included in follow-up at annual 
time points. Anti-TNF, anti-tumour necrosis factor; DMARD, disease-
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been higher in the DMARD cohort. Unfortunately, despite our 
efforts to do so, it was not possible to collect robust high-quality 
data retrospectively about baseline RA-ILD severity.
The proportion of deaths where RA-ILD was recorded on 
the death certiﬁ  cate was higher in the anti-TNF-treated RA-ILD 
cohort. The proposed selection bias favouring less severe 
RA-ILD in the anti-TNF cohort would not explain this ﬁ  nding. 
Alternative explanations include anti-TNF therapy truly increas-
ing the proportion of deaths attributable to RA-ILD, or clinicians 
being more inclined to report RA-ILD on the death certiﬁ  cates 
of patients treated with anti-TNF therapy. Given the existing 
safety concerns, this latter possibility is plausible.
Less than 3% of patients in this study were reported to have 
baseline RA-ILD, despite the BSRBR population including only 
patients with severe active RA. Although estimates of the preva-
lence of RA-ILD in the literature vary according to the deﬁ  ni-
tion of RA-ILD, the cohort under study and the investigation 
technique, values range from 1% to 80%.1 28–30 Our low preva-
lence of 2.6% would support the suggestion that physicians are 
identifying only a proportion of the patients who have RA-ILD. 
As a benchmark of RA-ILD mortality, a UK inception cohort of 
patients with RA treated in the prebiological era reported 4% 
of deaths due to RA-ILD,7 which is comparable to the 3% of 
deaths attributable to RA-ILD in the BSRBR DMARD cohort. 
Our ﬁ  nding of a nearly threefold higher mortality in patients 
with RA-ILD than in patients with no RA-ILD replicates recent 
results from the Mayo Clinic.31
An observational study by Wolfe et al has previously 
attempted to investigate the association between anti-TNF 
  therapy and the risk of hospitalisation for RA-ILD.32 Although 
they reported a univariate association between prior anti-TNF 
use and   hospitalisation for RA-ILD, the authors acknowledge 
this probably represents confounding by indication, concluding 
that they were unable to make any inference about causality.
Despite initial concerns about the safety of anti-TNF therapy 
in patients with RA-ILD, our study has not found an increased 
rate of mortality. This is reassuring, and suggests that UK clini-
cians are currently making appropriate decisions about which 
patients with RA-ILD to treat with anti-TNF. However, it should 
not be assumed that it is safe to prescribe anti-TNF therapy to 
unselected patients with RA-ILD. Our analysis does not enable 
us to advise on whether patients should be screened prior to 
treatment, how patients should be selected for treatment, or how 
patients should be monitored once treatment is commenced.
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